Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.34 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.90 | 0.73 | 0.83 | 0.62 | 0.64 | 0.62 | 0.59 | 0.67 | 0.46 | 0.43 | 0.52 | 0.45 | 0.63 |
| — | +17.7% | +41.3% | -7.8% | +40.7% | +43.4% | +13.0% | +48.8% | -26.7% | -39.8% | -42.1% | -48.9% | -43.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -33.9% | -12.4% | -9.6% | -8.1% | -7.5% | -6.7% | -8.3% | -11.9% | -6.9% | -5.6% | -4.6% | -5.6% | -5.3% |
| — | -85.5% | -16.0% | +32.4% | -8.5% | -19.0% | -78.9% | -111.6% | -30.4% | -359.3% | +1.2% | +6.9% | -129.1% | |
| ROA | -31.8% | -11.4% | -8.9% | -7.6% | -7.0% | -6.2% | -7.6% | -11.0% | -6.5% | -5.4% | -4.5% | -5.4% | -5.1% |
| — | -84.0% | -17.3% | +31.2% | -7.8% | -15.8% | -70.9% | -102.4% | -28.0% | -359.8% | -0.4% | +3.7% | -135.1% | |
| ROIC | -36.7% | -13.2% | -10.9% | -8.8% | -7.9% | -9.3% | -12.1% | -13.8% | -8.1% | -7.3% | -6.4% | -14.3% | -12.3% |
| — | -41.3% | +10.4% | +36.5% | +2.3% | -28.0% | -90.1% | +3.8% | +33.9% | -40.4% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 13.8% YoY to 16.66x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | -17.3% | -19.6% | -19.9% | -13.5% | -9.9% | -7.4% | -7.9% | -11.3% | -10.6% | -13.2% | +12.6% | +1660.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 24.85 | 16.66 | 19.17 | 19.94 | 24.85 | 19.33 | 19.02 | 13.28 | 18.24 | 31.93 | 38.42 | 51.16 | 35.77 |
| — | -13.8% | +0.8% | +50.1% | +36.3% | -39.5% | -50.5% | -74.0% | -49.0% | -26.8% | +39.9% | +105.2% | +163.4% | |
| Quick Ratio | 24.85 | 16.66 | 19.17 | 19.94 | 24.85 | 19.33 | 19.02 | 13.28 | 18.24 | 31.93 | 38.42 | 51.16 | 35.77 |
| — | -13.8% | +0.8% | +50.1% | +36.3% | -39.5% | -50.5% | -74.0% | -49.0% | -26.8% | +39.9% | +105.2% | +163.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAtea Pharmaceuticals, Inc.'s current P/E is -2.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Atea Pharmaceuticals, Inc.'s business trajectory between earnings reports.